FDA Advisory Panel Votes 10-0 for Fast Approval of Seattle Genetics Hodgkin Drug

by Patrick Henderson, Benzinga Staff Writer
July 14, 2011 11:36 AM | 5 seconds read |
Panel says Seattle Genetics SGEN should do follow-up trial for regular approval.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!